Damiani Giovanni, Diani Marco, Conic Rosalynn R Z, Colli Laura, Ferrucci Silvia, Martina Emanuela, Offidani Anna Maria, Pigatto Paolo Daniele Maria
Young Dermatologists Italian Network (YDIN), GISED, Bergamo, Italy,
Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy,
Int Arch Allergy Immunol. 2019;178(1):45-49. doi: 10.1159/000492532. Epub 2018 Nov 5.
Omalizumab is approved for use in chronic spontaneous urticaria (CSU); however, it is not approved for chronic inducible urticaria (CIndU). The aim of the present study was to assess the effectiveness of omalizumab in treating CSU and CIndU in Italy. This is a multicentre prospective observational real-life study involving patients with severe urticaria capable of undergoing omalizumab therapy. We enrolled 127 patients (59.1% females), ranging in age from 15 to 83 years, 69.3% had CSU alone, 26.8% had CSU and CIndU, and 3.9% had only CIndU (30.8% delayed pressure, 35.9% dermographic, 15.3% cholinergic, 12.8% cold, 5.1% aquagenic). After the first cycle of omalizumab (300 mg every 4 weeks for 24 weeks), 16 CSU patients and 10 patients (20.5%) with CIndU with or without CSU did not require a second cycle of omalizumab (300 mg every 4 weeks for 20 weeks). The patient with aquagenic urticaria achieved remission after the first cycle. None showed a lack of response to the second cycle of omalizumab. Omalizumab is a promising drug for both spontaneous and inducible chronic urticaria. Current evidence indicates that omalizumab may be approved also for CIndU.
奥马珠单抗被批准用于慢性自发性荨麻疹（CSU）；然而，它未被批准用于慢性诱导性荨麻疹（CIndU）。本研究的目的是评估奥马珠单抗在意大利治疗CSU和CIndU的有效性。这是一项多中心前瞻性观察性现实生活研究，纳入了能够接受奥马珠单抗治疗的重度荨麻疹患者。我们招募了127名患者（女性占59.1%），年龄在15至83岁之间，其中69.3%仅患有CSU，26.8%患有CSU和CIndU，3.9%仅患有CIndU（迟发性压力性30.8%、皮肤划痕症35.9%、胆碱能性15.3%、寒冷性12.8%、水源性5.1%）。在奥马珠单抗的第一个疗程（每4周300 mg，共24周）后，16名CSU患者以及10名（20.5%）患有或未患有CSU的CIndU患者不需要第二个奥马珠单抗疗程（每4周300 mg，共20周）。水源性荨麻疹患者在第一个疗程后实现缓解。没有人对奥马珠单抗的第二个疗程无反应。奥马珠单抗对于自发性和诱导性慢性荨麻疹都是一种有前景的药物。目前的证据表明奥马珠单抗也可能被批准用于CIndU。
